===
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE'S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK
RADIO WITH ELLIS MARTIN
2024-06-17 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE'S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK
RADIO WITH ELLIS MARTIN

Vancouver, BC, Canada, June 17th, 2024 - Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB:
DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery
technologies, is please to share the interview of Dr. Moutih Rafei, Defence's Chief Scientific Officer, with Ellis
Martin on Money Talk Radio.
To Listen to the Interview, please visit:
https://www.abnnewswire.net/lnk/7D1OV2C6
About The Ellis Martin Report:
The Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an
audience of potential retail investors and fund managers that comprise its listening audience. TEMR is broadcasted on
the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those
represented on the program.

About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next
generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the
ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious
diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this
release, other than statements of historical facts, that address events or developments that the Company expects to
occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may",
"could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include regulatory actions, market prices, and continued
availability of capital and financing, and general economic, market or business conditions. Investors are cautioned
that any such statements are not guarantees of future performance and actual results or developments may differ
materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of the Company's management on the date the statements are made. Except as required by
applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the
event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility
for the adequacy or accuracy of this release.


2024-06-17 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Defence Therapeutics Inc. 

1680 - 200 Burrard St
V6C3L6 Vancouver
Canada

E-mail:       info@defencetherapeutics.com 
Internet:     https://defencetherapeutics.com 
ISIN:         CA24463V1013 
WKN:          A3CN14 
Listed:       Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto 
EQS News ID:  1926001 

End of News EQS News Service
===
1926001 2024-06-17 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1926001&application_name=news

END) Dow Jones Newswires

June 17, 2024 02:00 ET (06:00 GMT)